News | October 23, 2025
Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Subscribe To Our Newsletter & Stay Updated
